CTRI/2023/03/050758招募中4 期
Efficacy and safety of G-Amrita formulation in the management of high uric acid and gouty arthritis
Shree Dhanwantri Herbals0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •With the data of serum uric acid level more than 8.0 mg/dl
排除标准
- •1. Significant liver or Renal dysfunction, Hematological disease, Oncological disease, or other life threatens disorders.
- •2.Condition that need the management of diuretics or analgesics agent
- •3.Severe cerebrovascular disease or severe heart disease;
- •4.Mental diseases such as schizophrenia, depressive disorder, and drug dependence
- •5.Alcohol abuse or dependence
- •6.Aspartate aminotransferase (GOT) or alanine aminotransferase (GPT) level 2 times higher than the normal upper limit;
- •7.Creatinine higher than 2 mg/dl
- •8.Pregnant, lactating, or planning to become pregnant within 3 months;
研究者
相似试验
已完成
3 期
A clinical trial to study the effects of two drugs, Agomelatine and Venlafaxine ER in patients with major depressive disorder.CTRI/2011/04/001659Sun Pharmaceutical Industries Ltd200
进行中（未招募）
不适用
ong-term efficacy and safety of agomelatine in non-depressed out-patients with Generalized Anxiety Disorder.A 26-week randomised double-blind placebo-controlled parallel group study following an open-label period of 16 weeks with agomelatine (25mg/day with the possibility for blinded dose-adjustment to 50mg/day).Generalised anxiety disorderMedDRA version: 10.0Level: LLTClassification code 10018075Term: <Manually entered code. Term in E.1.1>EUCTR2006-005674-47-EEInstitut de Recherches Internationales Servier500
进行中（未招募）
1 期
ong-term efficacy and safety of agomelatine in non-depressed out-patients with Generalized Anxiety Disorder.A 26-week randomised double-blind placebo-controlled parallel group study following an open-label period of 16 weeks with agomelatine (25mg/day with the possibility for blinded dose-adjustment to 50mg/day).EUCTR2006-005674-47-DKInstitut de Recherches Internationales Servier370
进行中（未招募）
不适用
ong-term efficacy and safety of agomelatine in non-depressed out-patients with Generalized Anxiety Disorder.A 26-week randomised double-blind placebo-controlled parallel group study following an open-label period of 16 weeks with agomelatine (25mg/day with the possibility for blinded dose-adjustment to 50mg/day).Generalised anxiety disorderMedDRA version: 10.0Level: LLTClassification code 10018075Term: <Manually entered code. Term in E.1.1>EUCTR2006-005674-47-FIInstitut de Recherches Internationales Servier500
进行中（未招募）
1 期
ong-term efficacy and safety of agomelatine in non-depressed out-patients with Generalized Anxiety Disorder.A 26-week randomised double-blind placebo-controlled parallel group study following an open-label period of 16 weeks with agomelatine (25mg/day with the possibility for blinded dose-adjustment to 50mg/day).Generalised anxiety disorderMedDRA version: 10.0Level: LLTClassification code 10018075Term: <Manually entered code. Term in E.1.1>EUCTR2006-005674-47-HUInstitut de Recherches Internationales Servier500